Our mission:

  • A multi-disciplinary, collaborative alliance of University of Washington health sciences research groups focused on comparative effectiveness research, technology assessment, and health system evaluation
  • Community of engaged peers, research teams and like-minded collaborators
  • Builds upon existing and available resources and creates economies of scale for high-impact research

UW CHASE Pictorial

News & Events


May 20
PORPP awarded new AHRQ K-12 institutional training program to support mentored career development research training in comparative effectiveness research. Trainees will have protected time for research training and complete short-term practicum experiences with Washington State Health Technology Assessment Program, Premera Blue Cross Health Technology Assessment and Medical Policy Program, or Group Health Research Institute. Dr. Sean Sullivan will serve as Program Director and several CHASE Alliance affiliated faculty will serve as trainee mentors.
SORCE awarded a new NIDDK R01 “Feasibility, Efficacy, and Mechanisms of Surgical vs. Medical Diabetes Treatment”. Co-PIs Drs. David Flum and David Cummings of the Diabetes Endocrinology Research Center will partner with Dr. David Arterburn at Group Health Research Institute and other endocrinology colleagues in a translational effort to understand the comparative benefits of treatment options for diabetic patients with BMI 30-40 kg/m2.
April 1
SORCE awarded NIDDK T32 training grant for Gastrointestinal Surgery Outcomes Research Fellowship, to support 2 research fellows per year.
UW Professor Dr. Dedra Buchwald and colleagues awarded NCI Population Health Center grant for the "Collaborative to Improve Native Cancer Outcomes," or CINCO Dr. David R. Flum and SORCE will lead one center project evaluationg surgical disparities in the treatment of lung, breast, colorectal, adn prostate cancer in American Indians and Alaskan Natives.

Upcoming Events

May 25
UW Outcomes Research Collaborative, 7:30-9am, UW Health Sciences RR401
Presenter: Melissa Thrall, MD
June 1
CHASE Symposium: Evidence and Clinical Decisions in the Era of Health Care Reform; Nicky Cullum & Mark Sculpher, University of York
Hosted by Sean Sullivan and Larry Kessler, UW; John Watkins, Premera BlueCross
April 14
PORPP Seminar: 12-1pm, UW Health Sciences H-074
Newer Agents for Advanced Non-Small-Cell Lung Cancer: Evidence from the NCI Patterns of Care Study, Bernardo Goulart
June 22
UW Outcomes Research Collaborative, 7:30-9am, UW Health Sciences RR401

Research Spotlight

Advancing Innovative Comparative Effectiveness Research in Cancer Diagnostics (ADVICE)

PIs: Larry Kessler, ScD and Sean D. Sullivan, PhD
Centers: UW Health Services, PORPP

In this study funded under the NIH ARRA Grand Opportunity grants, co-PIs Drs. Kessler and Sullivan and colleagues at FHCRC are working towards establishing a multi-disciplinary and cross-institutional network of health delivery systems and researchers in Western Washington State for evaluating the comparative effectiveness of cancer diagnostics in real-world settings. Cancer diagnostics are at the forefront of medical technology and ADVICE is unique in bringing together an entire community of care delivery systems, including major fee-for-service plans such as Premera Blue Cross and Regence Blue Shield, with publicly funded systems such as Medicaid, with a major integrated health care deliverer, Group Health Cooperative, along with the UW School of Public Health as convener of the effort, a leading edge comprehensive cancer center Fred Hutchinson Cancer Research Center, and an ideal group of persons who have expertise in CER along major delivery systems where CER should make a difference in how care is deployed. The ADVICE grant allows development of a solid infrastructure to test scientific and policy relevant comparative effectiveness research questions involving wide community representation, and a process that allows a continuous, community-CER based process for the future. The first ADVICE study we will undertake is a comparative effectiveness assessment of diagnostic tools used for establishing extent of disease among newly diagnosed Stage I – III breast cancer. For more information about this study, please contact chaseall@uw.edu.